Dimensional Fund Advisors LP Buys 59,353 Shares of Globe Life Inc. $GL

Dimensional Fund Advisors LP raised its stake in shares of Globe Life Inc. (NYSE:GL) by 2.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,076,232 shares of the company’s stock after purchasing an additional 59,353 shares during the period. Dimensional Fund Advisors LP owned 2.61% of Globe Life worth $296,841,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Picton Mahoney Asset Management bought a new stake in shares of Globe Life during the 3rd quarter worth $8,890,000. Victory Capital Management Inc. grew its stake in Globe Life by 2.2% in the 3rd quarter. Victory Capital Management Inc. now owns 445,639 shares of the company’s stock valued at $63,713,000 after buying an additional 9,505 shares during the last quarter. 111 Capital bought a new position in Globe Life in the 3rd quarter worth $371,000. Journey Strategic Wealth LLC increased its stake in shares of Globe Life by 5.0% in the third quarter. Journey Strategic Wealth LLC now owns 2,103 shares of the company’s stock worth $301,000 after purchasing an additional 101 shares during the period. Finally, American Century Companies Inc. lifted its position in shares of Globe Life by 0.7% during the 3rd quarter. American Century Companies Inc. now owns 288,363 shares of the company’s stock worth $41,227,000 after purchasing an additional 2,029 shares during the last quarter. 81.61% of the stock is currently owned by institutional investors and hedge funds.

Globe Life Trading Down 0.7%

Shares of GL stock opened at $142.41 on Friday. The firm has a fifty day moving average of $142.04 and a 200-day moving average of $138.96. The stock has a market cap of $11.20 billion, a price-to-earnings ratio of 10.11 and a beta of 0.46. Globe Life Inc. has a 52-week low of $109.38 and a 52-week high of $152.71. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.07 and a current ratio of 0.07.

Globe Life (NYSE:GL) last issued its earnings results on Wednesday, February 4th. The company reported $3.39 earnings per share for the quarter, missing the consensus estimate of $3.44 by ($0.05). Globe Life had a net margin of 19.37% and a return on equity of 21.30%. The business had revenue of $1.52 billion for the quarter, compared to analyst estimates of $1.53 billion. During the same quarter last year, the firm posted $3.14 earnings per share. Globe Life’s revenue was up 3.6% on a year-over-year basis. Globe Life has set its FY 2026 guidance at 14.950-15.650 EPS. On average, equities research analysts forecast that Globe Life Inc. will post 13.87 earnings per share for the current fiscal year.

Globe Life Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Friday, April 3rd will be paid a $0.33 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $1.32 annualized dividend and a yield of 0.9%. This is a positive change from Globe Life’s previous quarterly dividend of $0.27. Globe Life’s payout ratio is presently 7.67%.

Insider Buying and Selling

In related news, CMO Jennifer Allison Haworth sold 10,000 shares of Globe Life stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $143.14, for a total transaction of $1,431,400.00. Following the completion of the transaction, the chief marketing officer directly owned 17,479 shares of the company’s stock, valued at $2,501,944.06. This trade represents a 36.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO James Matthew Darden sold 18,318 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $145.10, for a total transaction of $2,657,941.80. Following the completion of the transaction, the chief executive officer owned 51,093 shares in the company, valued at approximately $7,413,594.30. This trade represents a 26.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 92,186 shares of company stock worth $13,358,379 in the last three months. Company insiders own 1.51% of the company’s stock.

Wall Street Analysts Forecast Growth

GL has been the subject of several recent analyst reports. Weiss Ratings upgraded Globe Life from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, February 13th. JPMorgan Chase & Co. upped their price target on Globe Life from $180.00 to $181.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Wells Fargo & Company increased their price objective on Globe Life from $170.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Morgan Stanley restated an “overweight” rating and issued a $176.00 price objective on shares of Globe Life in a research note on Monday, December 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $167.00 target price on shares of Globe Life in a research report on Friday, November 21st. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Globe Life Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.